Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 562 Documents

18 19 20 21 22

Cervical Cancer Risk Factors Association in Patients at the Gynecologic-Oncology Clinic of Dr. Soetomo Hospital Surabaya Aisyiah Rahmi Putri; Siti Khaerunnisa; Indra Yuliati
Indonesian Journal of Cancer Vol 13, No 4 (2019): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Cervical cancer ranks fourth of all cancers in women worldwide and linked to human papillomavirus (HPV) infection. Despite the evidence of methods for cervical cancer prevention, such as pap smear test and HPV vaccination, most of the women remain unscreened and never get HPV vaccination. Most cervical cancer cases are not diagnosed early enough, leading to poor outcomes. This study aims to examine the association of risk factors with cervical cancer incidence in Dr. Soetomo Hospital Surabaya and also records the patients’ knowledge of cervical cancer preventions, history of HPV vaccination, and pap smear screening test.Methods: This is a case-control study. Questionnaires were given to 60 newly diagnosed cervical cancer patients and 60 non-cervical cancer patients at The Gynecologic-Oncology Clinic of Dr. Soetomo Hospital Surabaya in the period of March 2016 until August 2016. The analysis was made using bivariate and multivariate logistic regression analysis.Results: The bivariate logistic regression analysis confirmed that parity more than two times (p=0.001), history of birth control pills consumption more than 10 years (p=0.04), passive smoking (p=0.001) and not knowing that cervical cancer can be prevented (p=0.001) were significantly associated to the incidence of cervical cancer. The multivariate logistic regression analysis confirmed that not knowing that cervical cancer can be prevented (OR=6.85), the history of passive smoking (OR=4.04), parity more than two times (OR=2.89) and history of birth control pills consumption more than 10 years (OR=6.52) were the independent factors that were associated with the cervical cancer incidence.Conclusions: Parity more than two times, history of birth control pills consumption more than 10 years, history of passive smoking, not knowing that cervical cancer can be prevented and never having a pap smear test were the factors associated with cervical cancer incidence.

Therapeutic Responses of Imatinib and Nilotinib among CML Patients in Hasan Sadikin Hospital Bandung Agung Firmansyah Sumantri; Amaylia Oehadian; Indra Wijaya; Putri Vidyaniati; Rahmaniati Rahmaniati
Indonesian Journal of Cancer Vol 12, No 3 (2018): July-September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative malignancy with an estimated incidence in the world of 1-2 cases per 100,000 adults. The use of Tyrosine Kinase Inhibitors (TKI) as a therapy for CML is still the first choice for treatment, but some cases show a high level of resistance or intolerance to TKI therapy. This study aims to identify the therapeutic responses of imatinib and nilotinib among CML patients in Bandung.Method: This study is an analytical descriptive study of CML patients at Hasan Sadikin Hospital’s Hematology and Medical Oncology Outpatient Clinic in 2017. The total number of samples in this study is 244 patients, consisting of 199 patients with Imatinib therapy and 45 patients with Nilotinib therapy. The data is processed using SPSS Statistics 22.0 software.Result: The results showed that CML patients had a median age of 42 years, sex ratio of 1: 1 and the highest prevalence was in Bandung City (21.3%). Hematologic response is dominated by complete hematologic response, as high as 72.86% with Imatinib and 66.67% with Nilotinib. Molecular response 3-6 months post therapy is dominated by suboptimal response in as many as 36,8% with Imatinib and failure in as many as 50% with Nilotinib. Molecular response 12-18 months post therapy is dominated by failure in as high as 69,4% with Imatinib and 52,4% with Nilotinib.Conclusion: Based on the molecular response, the rates of suboptimal response and resistance are quite high. Regular monitoring standards of therapy for CML patients are needed to identify TKI resistance so alternative therapies can be provided to improve the outcomes.

Ekspresi p53 Mutan dan caspase 3 sebagai Faktor Prediksi terhadap Operabilitas Kanker Serviks IIB setelah Mendapat Kemoterapi Neoajuvan Teguh Prakosa; Brahmana Askandar; Dyah Fauziah
Indonesian Journal of Cancer Vol 7, No 2 (2013): Apr - Jun 2013
Publisher : National Cancer Center - Dharmais Cancer Hospital

Tujuan: untuk mengetahui ekspresicaspase3 dan p53 mutan dalam memprediksi respons operabilitas (pra-operatif) pada penderita kanker serviks IIB yang mendapatkan kemoterapi neoajuvanpaclitaxel-platinum.Metode: ekspresicaspase3 dan p53 mutan diperiksa dengan pengecatan immunohistokimia pada 40 potongan biopsi jaringan pasien kanker serviks IIB yang memenuhi kriteria inklusi, yang melakukan pengobatan di RSUD dr. Soetomo, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Airlangga, Surabaya mulai bulan Desember 2006 hingga Juli 2011. Kriteria inklusi meliputi penderita kanker serviks IIB yang mendapatkan rejimen kemoterapi neoajuvanpaclitaxel-platinum(cisplatin 75 mg/m2 atau carboplatin AUC 5 paclitaxel175 mg/m2) sebanyak tiga seri berturut-turut 3 mingguan dan telah dilakukan evaluasi operabilitasnya pasca-kemoterapi neoajuvan yang dilakukan sebelum operasi, 3 minggu sampai 4 minggu setelah kemoterapi yang terakhir. Penelitian ini merupakan studi analitik dengan studi kasus kontrol.Hasil: hubungan antara ekspresi p53 mutan dancaspase3 dengan operabilitas post kemoterapi neoajuvanpaclitaxel-platinumdianalisis dengan uji regresi logistik sederhana. Dari penelitian ini didapatkan sejumlah 22 (55%) pasien kanker serviks IIB yang mendapat kemoterapi neoajuvan memberikan responsinoperabledan 18 (45%) pasien memberikan respons operabel. Ekspresi p53 mutan terbanyak menunjukkan hasil ekspresi negatif, dengan rentang skor 0-1, yaitu sebanyak 33 (82,5%) penderita. Ekspresi positif didapatkan pada 7 (17,5 %) penderita, dan tidak didapatkan perbedaan yang signifikan (p 0,48; OR: 0,55 (CI 95%:0,11-2,87)). Jumlah ekspresicaspase3 yang positif dan negatif menunjukkan jumlah yang sama besarnya baik pada luaran inoperabel maupun operabel, yaitu masing-masing 13 (72,2%) dan 11 (50,0%); dengan p=0,158, OR:2,60(CI 95%:0,69-9,81).Kesimpulan: ekspresicaspase3 dan p53 mutan tidak dapat memprediksi respons operabilitas pada pasien kanker serviks IIB yang mendapatkan kemoterapi neoajuvanpaclitaxel-platinum.Kata kunci: kanker serviks stadium IIB, kemoterapi neoajuvanpaclitaxel-platinum, operabilitas pascakemoterapi neoajuvan

Penerapan Solution-Focused Brief Therapy dalam Meningkatkan Self-Esteem pada Remaja Perempuan Penderita Leukemia JESSICA MIRANDA; SOEMIARTI PATMONODEWO; NAOMI SOETIKNO; EDI SETIAWAN TEHUTERU
Indonesian Journal of Cancer Vol 11, No 2 (2017): April - June
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACT The diagnosis of cancer have an impact on physical and psychological development of adolescent. Psychological impact is felt with the emergence of some emotional reactions, such as fear, anxiety, sadness, despair, anger, guilt, and shame. Adolescents who experience physical and psychological impact of the treatment of the cancer will experience problems in self-esteem and body image, that have an impact on the development of adolescent self until early adulthood. The establishment of self-esteem need to occur in adolescence. In adolescence, the individual will develop a positive sense of self so that adolescence is an important period for individuals to establish self-esteem, because at this time many changes occur both physically and emotionally. This study was conducted to help improve self-esteem in young woman with leukimia with solution-focused brief therapy. The participant of this study was two participants adolescent female with early-stage leukimia ALL types for two years. This therapy was conducted in three weeks by researcher herself. Researcher used questionnaries measuring selfesteem and graphics tests before and after the intervention to measure the role of therapy programs. Solution-focused brief therapy used in this study shows no role to improve the self-esteem of adolescent female patients with leukimia. This is because the PA subjects only increased by 2 points and subjects SS increased scores by 10 points ABSTRAK Diagnosis kanker memiliki dampak fisik dan psikologis bagi perkembangan remaja. Dampak psikologis yang dirasakan berupa timbulnya beberapa reaksi emosional, seperti takut, cemas, sedih, putus asa, marah, merasa bersalah, dan malu. Remaja yang mengalami dampak fisik dan psikologis dari pengobatan kanker yang dideritanya akan mengalami permasalahan pada self-esteem dan body image yang berdampak pada pengembangan diri remaja tersebut hingga masa dewasa awal. Pembentukan self-esteem terjadi pada masa remaja. Pada masa remaja individu akan mengembangkan sense of self yang positif sehingga masa remaja merupakan masa yang penting bagi individu untuk membentuk self-esteem, karena pada masa ini banyak terjadi perubahan-perubahan, baik secara fisik maupun emosi. Penelitian ini dilakukan untuk membantu meningkatkan self-esteem pada remaja perempuan penderita leukemia dengan solution-focused brief therapy. Penelitian ini dilakukan terhadap dua partisipan remaja perempuan penderita leukemia jenis ALL stadium awal selama dua tahun. Proses pemberian terapi dilakukan selama 3 minggu. Peneliti menggunakan alat ukur “Kuesioner Harga Diri” serta tes grafis sebelum dan sesudah intervensi untuk mengukur peranan program terapi. Solution-focused brief therapy yang digunakan dalam penelitian ini menunjukkan bahwa terapi tersebut tidak berperan dalam meningkatkan self-esteem remaja perempuan penderita leukemia. Hal ini dikarenakan subjek PA hanya mengalami peningkatan skor sebesar 2 poin dan subjek SS mengalami peningkatan skor sebesar 10 poin

Kemoembolisasi Transarterial (TACE) pada Karsinoma Hepatoselular (KHS) Bagaswoto Poedjomartono; Sudarmanto -
Indonesian Journal of Cancer Vol 3, No 3 (2009): Jul - Sep 2009
Publisher : National Cancer Center - Dharmais Cancer Hospital

Karsinoma hepatoselular (KHS) merupakan 5,6% dari seluruh kanker pada manusia. KHS menempati urutan ke-5 pada laki-laki dan ke-9 pada wanita. KHS juga menempati urutan ke-3 dari kanker sistem gastrointestinal setelah kanker kolorektal dan kanker lambung. Tingkat kematiannya sangat tinggi, menempati urutan ke-2 setelah kanker pankreas. Insiden karsinoma hepatoselular (KHS) di Asia Tenggara relatif tinggi pada laki-laki (18,35) dan wanita 5,70 per 100.000 penduduk. KHS mempunyai hubungan kuat dengan infeksi kronik virus hepatitis B (HBV), baik secara epidemiologis, klinis, maupun eksperimental. Karsinoma hepatoselular (KHS) juga mempunyai hubungan dengan virus hepatitis C (HCV), sirosis hati, aflatoxin, obesitas, diabetes melitus, dan alkohol.Diagnosis karsinoma hepatoselular (KHS) dapat ditegakkan dengan pemeriksaan biopsi sitohistologis, laboratorium, dan radiologi. Pemeriksaan laboratoris AFP yang sama atau lebih dari 400 ng/mL dan imajing USG sudah dapat digunakan sebagai parameter diagnosis karsinoma hepatoselular (KHS). Sedang pemeriksaan dengan CT atau MRI dapat mengidentifikasi adanya nodul hipervaskular arteri pada penyakit hati yang kronis.Pada KHS stadium dini, sebelum timbul vaskular yang dominan, bedah merupakan terapi pilihan. Tetapi, jika sudah timbul vaskularisasi yang dominan maka terapi kombinasi di antara bedah, ablasi, dan chemo dapat merupakan pilihan. Sedangkan pada tahap yang sudah menengah lanjut, terapi TACE merupakan pilihan.Keywords: KHS, KHS stadium menengah lanjut, TACE

Nutrisi pada Pasien Kanker Yang Mendapat Kemoterapi Noorwati Sutandyo
Indonesian Journal of Cancer Vol 1, No 4 (2007): Oct - Dec 2007
Publisher : National Cancer Center - Dharmais Cancer Hospital

Dukungan nutrisi merupakan bagian dari terapi suportif pada kanker. Tujuan terapi nutrisi pada pasien kanker dititikberatkan terutama pada efek potensial dalam meningkatkan kualitas hidup. Kondisi nutrisi yang cukup berhubungan dengan prognosis yang baik. Kemoterapi merupakan terapi yang bertujuan untuk menghentikan pertumbuhan sel kanker, namun memiliki efek samping yang berhubungan dengan gangguan saluran cerna dengan manifestasi kurangnya asupan makanan dan gangguan pencernaan selama kemoterapi. Skrining dan evaluasi nutrisi secara dini dapat mengidentifikasi masalah yang mungkin mempengaruhi keberhasilan terapi kanker. Penemuan masalah nutrisi dan terapinya membantu pasien meningkatkan respon terapi dan menurunkan komplikasi.Kata kunci: nutrisi, pasien kanker, kemoterapi

Breast Cancer in West Java: Where Do We Stand and Go? Yohana Azhar; Hasrayati Agustina; Maman Abdurahman; Dimyati Achmad
Indonesian Journal of Cancer Vol 14, No 3 (2020): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Breast cancer is the most common cancer in Indonesia, a low-middle income country in Southeast Asia. We provide a regional hospital-based cancer registry of the central hospital in West Java, Indonesia. This study aims to characterize the presentation, diagnosis, evaluation, and management of breast cancer; to develop a regional breast cancer registry in West Java to monitor cancer care patterns; to evaluate cancer treatment outcomes.Methods: The data were collected from the medical records deposited in the Hasan Sadikin General Hospital Information System. The team has been contracted to operate the registry & organize an advisory board to standardize definitions of coding terminology of the registry’s reporting system and to monitor the cancer care pattern. Data validation was conducted by a team in the cancer registry, consisting of health officers, pathologists, and registrars. Data management and analysis were conducted by the cancer registry team.Results: A total of 913 women diagnosed with breast cancer, from January 2014 until December 2018, were studied. The median age was 49.5 years old. The initial diagnosis was at the age of 42.4 years old on average. About 64.5% were diagnosed with stage-3 and -4 cancers, and 75.1% had undergone a mastectomy, of which 47.3% of the intent was palliative. Of those who have hormonal receptors, only 26.9% were positive, and 36.5% were not assessed for immunohistochemistry evaluation. Inappropriate surgical management of breast cancer was common at the community level, which included indiscriminate diagnostic lumpectomy (21.9%), incomplete mastectomy and omission, or suboptimal lymph node axillary clearance (47.4%). Only 3.0% of patients received breast-conserving surgery and were treated with mastectomy and reconstruction. Conclusions: Breast cancer in West Java is often recognized at the late stage. Treatment was suboptimal, leading to poor survival. A more aggressive approach to early detection and treatment needs to be developed to improve the outcomes of this potentially curable disease.

Hubungan Genotipe DNA Human Papillomavirus (HPV) terhadap Respons Terapi Radiasi pada Karsinoma Sel Skuamosa Serviks CUT ADEYA ADELLA
Indonesian Journal of Cancer Vol 8, No 4 (2014): Oct - Dec 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

The importance of human papilloma virus (HPV) infection in the outcome of cervical cancer after radiotherapy remains unknown. Our study explored whether the HPV status of tumors is associated with the outcome of radiotherapy in patients with cervical cancer. The biopsy cervix samples taken from 31 patients with squamous cell carcinoma cervix (Stage IIB-IIIB) that met in the inclusion criteria. The HPV were genotyping examination was conducted twice before and 3 month after radiation therapy. The subjects treated by radiation therapy according to standard procedures. After undergone complete radiation, response of radiation therapy was conducted by clinical assessment and repeat HPV genotyping test. A total of 31 patients had HPV-positive tumors in 83.37% (27 cases) of patients, with the details of a single infection of 75% and 9:37% multiple infections. Based on the type of HPV type 16 was obtained (43.74%), type 18 (18.64%). Persistent infection with HPV after radiation encountered by 34.61%. Complete clinical response observed in the single infection group number of 100%, while in the group of multiple infections by 33.3% (p = 0.115). While HPV infection settled with a complete clinical response by 32% (p = 0.346). There were no statistically relationships between clinical complete response with single or multiple HPV infection (p = 0.115). There were no statistically relationship between persistent HPV infection with complete clinical response. (p = 0.346)

Fertility-Sparing Surgery In Early Stage Cervical Cancer IN Gede Budiana; Tjokorda Gede Astawa Pemayun
Indonesian Journal of Cancer Vol 12, No 1 (2018): Jan - Mar
Publisher : National Cancer Center - Dharmais Cancer Hospital

Cervical cancer is a malignancy in women that cause major impacts, not only biologically, but also in various aspects of life. On patients during reproductive age, cervical cancer poses severe sexual and reproductive debilitation. Trend in the onset of first diagnosis is moving towards younger age, and mostly affect women in their reproductive age. This would give a bad impact on the sustainability of the patient’s reproductive function. Until now, fertilitysparing approach for the management of early-stage cervical cancer is still rare in Indonesia. However, some options of conservative surgical therapy are available for patients who desire fertility, namely conization, simple tracellectomy, radical trachelectomy, and also neoadjuvant chemotherapy. These options have been proven effective and safe, while maintaining patients’ reproductive functions. ABSTRAKKanker serviks merupakan suatu penyakit keganasan pada wanita yang memiliki dampak luas, tidak hanya pada tubuh penderita, namun juga berbagai aspek kehidupan penderita. Pada penderita di usia reproduktif, kanker serviks menimbulkan masalah seksual dan reproduksi yang berat bagi penderita. Kini usia dimana terjadinya kanker serviks mulai menunjukkan kecenderungan yang semakin muda yang tentunya memberikan dampak buruk terhadap keberlangsungan fungsi reproduksi pasien. Hingga saat ini, tatalaksana kanker serviks stadium awal dengan pendekatan fertility-sparing masih jarang dilakukan di Indonesia. Namun, beberapa pilihan terapi bedah konservatif tersedia bagi pasien yang menginginkan fertilitas, yakni konisasi, trakelektomi sederhana, trakelektomi radikal. hingga pemberian kemoterapi neo-adjuvant. Pilihan terapi ini telah terbukti efektif dan aman, serta mampu mem pertahankan fungsi reproduksi pasien.

Micro-RNA dan Implikasinya pada Kanker Siti Boedina Kresno
Indonesian Journal of Cancer Vol 5, No 3 (2011): Jul - Sep 2011
Publisher : National Cancer Center - Dharmais Cancer Hospital

MikroRNA (miRNA) merupakan keluarga RNA yang tidak menyandi (non-coding RNA) yang berfungsi mengatur ekspresi gen pada jalur transduksi sinyal seluler. Ia dapat bersifat onkogen atau gen supresor tumor, tergantung mRNA sasarannya dan berfungsi sebagai modulator translasi dan stabilitas mRNA serta berpotensi mempengaruhi berbagai jalur proliferasi, diferensiasi, dan apoptosis sel. Kelainan pada miRNA, baik ekspresi berlebihan maupun delesi, dapat berpengaruh pada berbagai proses seluler di atas dan berakibat transformasi ganas. Dalam beberapa tahun terakhir, berbagai jenis miRNA yang berperan pada keganasan telah dapat diidentifikasi, bahkan selain dalam jaringan tumor juga dapat diidentifikasi dan diukur kadarnya dalam serum dan cairan tubuh lain sebagaicirculatingmiRNA, sehingga di kemudian hari dapat digunakan sebagai biomarker non-invasif untuk diagnosis maupun prognosis dan pemantauan kanker.Katakunci : micro-RNA, cell-free-miRNA, regulator pasca-transkripsi

Page 20 of 57 | Total Record : 562

18 19 20 21 22

Filter by Year

2007 2025

Filter By Issues

All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA